Pharmacology of anticoagulants used in the treatment of venous thromboembolism

Journal of Thrombosis and Thrombolysis - Tập 41 Số 1 - Trang 15-31 - 2016
Edith A. Nutescu1, Allison Burnett2, John Fanikos3, Sarah A. Spinler4, Ann K. Wittkowsky5
1Department of Pharmacy Systems Outcomes and Policy and Center for Pharmacoepidemiology & Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
2Inpatient Antithrombosis Services, University of New Mexico Hospital, University of New Mexico College of Pharmacy, Albuquerque, NM, USA
3Brigham and Women’s Hospital, Massachusetts College of Pharmacy, Boston, MA, USA
4Philadelphia College of Pharmacy and Science, Philadelphia, PA, USA
5University of Washington School of Pharmacy, Seattle, WA, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Wells PS, Forgie MA, Rodger MA (2014) Treatment of venous thromboembolism. JAMA 31(7):717–728

Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S

Hirsh J (1991) Heparin. N Engl J Med 324:1565–1574

Hirsh J, Bauer KA, Donati MB et al (2008) Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:141–159

Weitz DS, Weitz JI (2010) Update on Heparin: what do we need to know? J Thromb Thombolysis 29:199–207

Bussey H, Francis J et al (2004) Heparin overview and issues. Pharmacotherapy 24:103S–107S

Bick R (2005) Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin N Am 19:1–51

Hull RD, Raskob GE, Hirsh J et al (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315:1109–1114

Raschke RA, Reilly BM, Guidry JR et al (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram: a randomized controlled trial. Ann Intern Med 119:874–881

Rosborough TK, Shepherd MF (2004) Achieving target anti-factor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 24:713–719

Schulman S, Beth RJ et al (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:257–298

Crowther MA, Warkentin TE (2008) Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111:4871–4879

Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th Ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e24S–e43S

Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184S

Campbell NR, Hull RD, Brant R et al (1996) Aging and heparin-related bleeding. Arch Intern Med 156:857–860

Walker AM, Jick H (1980) Predictors of bleeding during heparin therapy. JAMA 244:1209–1212

Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e326S–e350S

Levi M, Eerenberg E, Kamphuisen PW (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9:1705–1712

Schulman S, Bijsterveld NR (2007) Anticoagulants and their reversal. Transfus Med Rev 21:37–48

Protamine sulfate injection. AHFS Drug Information 2015. American Society of Health-System Pharmacists, Bethesda

Selleng K, Warkentin TE et al (2007) Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 35(4):1165–1176

Martel N, Lee J, Wells PS et al (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710–2715

Warkentin TE, Kelton JG (2001) Temporal aspects of Heparin-induced thrombocytopenia. N Engl J Med 344:1286–1292

Warkentin TE, Greinacher A et al (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:340–380

Weitz JI (1997) Low-molecular weight heparins. N Engl J Med 337:688–698

Fareed J, Hoppensteadt D, Walenga J, Igbal O, Jeske W, Sheikh T (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 42:1043–1057

Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26(Suppl 1):31–38

Lovenox (enoxaparin sodium injection) prescribing information. Sanofi Aventis U.S. LLC, Bridgewater. http://products.sanofi.us/lovenox/lovenox.html . Accessed 11 August 2015

Fragmin (dalteparin sodium for subcutaneous injection) prescribing information. Pfizer Injectables. New York. http://labeling.pfizer.com/ShowLabeling.aspx?id=2293 . Accessed 11 August 2015

Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43:1064–1083

Collignon F, Fryman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J et al (1995) Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73:630–640

Hasan K, Lazo-Langner A, Acedillo R, Zeller M, Hackam DG (2010) Anticoagulant response after dalteparin overdose. J Thromb Haemost 8:2321–2323

Wilson JM, Gilbert J, Harlan M, Bracey A, Allison P, Schooley C et al (2005) High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. Clin Appl Thromb Hemost 11:127–138

Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H et al (2002) The pharmacokinetics of fondaparinux sodium in health volunteers. Clin Pharmacokinet 41(Suppl 2):1–9

Arixtra (fondaparinux sodium solution for subcutaneous injection) prescribing information. GlaxoSmithKline. Research Triangle Park. http://www.gsk.ca/english/docs-pdf/product-monographs/Arixtra.pdf . Accessed 11 August 2015

Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49:761–772

Smogorzewska A, Brandt JT, Chandler WL, Cunningham MT, Hayes TE et al (2006) Effect of fondaparinux on coagulation assays: results of college of American Pathologists proficiency testing. Arch Pathol Lab Med 130:1605–1611

Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e120S–e151S

Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th Edition. American college of chest physicians evidence-based clinical practice guidelines. Chest 141(suppl 2):e44s–e88s

Ansell J, Hirsh J, Hylek E et al (2008) The pharmacology and management of the vitamin K antagonists. American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(Suppl 6):160s–198s

Stirling Y (1995) Warfarin-induced changes in procoagulant and anticoagulant proteins. Blood Coag Fibrinolysis 6:361–375

Breckenridge A, Orme M, Wessling H et al (1974) Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15:424–430

Hignite C, Uetriecht J, Tschanz C et al (1980) Kinetics of R and S warfarin enantiomers. Clin Pharmacol Ther 28:99–105

Chan E, McLachlan AJ, Pegg M et al (1994) Disposition of warfarin enantiomers and metabolism in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37:563–569

Warfarin Prescribing Information. Bristol-Myers Squibb. Princeton. http://packageinserts.bms.com/pi/pi_coumadin.pdf . Accessed 11 August 2015

Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Eur J Clin Pharmacol 65(4):365–375

Limdi NA, McGwin G, Goldstein JA et al (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312–321

Cavallari LH, Langaee TY, Momary KM et al (2010) Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87(4):459–464

Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4):1013–1021

Ng VL (2009) Anticoagulation monitoring. Clin Lab Med 28:283

Ng VL (2009) Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med 28:253

Kirkwood TB (1983) Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost 49:238–244

Hirsh J, Poller L (1994) The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 154:282–288

Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. Am J Clin Pathol 103:358–365

Spinler SA, Nutescu ED, Smythe MA et al (2005) Anticoagulation monitoring Part 1:warfarin and parenteral direct thrombin inhibitors. Ann Pharmacother 39:1049–1055

Wittkowsky AK (2006) Drug interactions with oral anticoagulants. In: Colman RW, Marder VJ, Clowes AW et al (eds) Hemostasis and thrombosis. Basic principals and clinical practice. 5th ed. Lippincott Williams & Wilkins, Philadelphia

Hansten P, Horn J (2010) Drug interactions analysis and management. Wolters Kluwer, St Louis

Daly AK, Aithal GP (2003) Genetic regulation of warfarin metabolism and response. Semin Vasc Med. 3:231–237

Pradaxa (dabigatran etexilate mesylate) prescribing information. Boehringer Ingelheim. Ridgefield. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf . Accessed 12 August 2015

Eliquis (apixaban prescribing information). Bristol-Myers Squibb Company. Princeton, NJ and Pfizer Inc. New York. http://packageinserts.bms.com/pi/pi_eliquis.pdf . Accessed 11 August 2015

Savaysa (edoxaban prescribing information). Daiichi Sankyo Inc., Parsippany. http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true . Accessed 13 August 2015

Xarelto (rivaroxaban) prescribing information. Janssen Pharmaceuticals. Titusville. https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf . Accessed 11 August 2015

Hellwig T, Gulseth M (2013) New oral therapies for the prevention and treatment of venous thromboembolism. AJHP 70:113–125

Cabral KP (2013) Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis 36:133–140

Funk DMA (2012) Coagulation assays and anticoagulant monitoring. ASH Education Book 1:460–465

Tripodi A, Siegal DM, Crowther MA, Garcia DA (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032–4035

Cuker A (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. JACC 64:1128–1139

Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15(Suppl 1):9S–16S

Stangier J, Rathgen K, Stähle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259–268

Van Ryn J, Stangier J, Haerrter S et al (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Throm Haemost 103:1116–1127

Baglin T, Hillarp A, Tripodi A et al (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. JTH 11:756–760

Frost C, Nepal S, Wang J et al (2013) Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76(5):776–786

Frost C, Yu Z, Shenker A, Nepal S (2008) Food does not affect the pharmacokinetics of apixaban, an oral factor Xa inhibitor. In: Abstract presentations: IXth world conference on clinical pharmacology and therapeutics. Can J Clin Pharmacol 15:e469. July 27, 2008 to August 1, 2008, Quebec City

Raghavan N, Frost C, Yu Z et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81

Frost C, Yu Z, Nepal S et al (2008) Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 48:1132

Frost C, Wang X, Barrett, et al. (2009) Abstracts of the XXII congress of the international society of thrombosis and haemostasis, Boston, July 2009. JTH abstract vol 7 (suppl 2): PP-MO-407

Upreti VV, Wang J, Barrett YC et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. BJCP 76:908–916

Frost C, Wang J, Li C et al (2009) Single-does safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther 85(suppl 1):s34

Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53:1–16

Kubitza D, Roth A, Becka M et al (2013) Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 76:89–98

Bounameaux H, Camm AJ (2014) Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 74:1209–1231

Becker RC, Yang H, Barrett Y et al (2011) Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban–an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 32:183–187

Bathala MS, Masumoto H, Oguma T et al (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab and Disp 40:2250–2255

Fuji T, Fujita S, Abe Y et al (2013) Evaluation of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. J Thromb Haemost 11(Suppl 2):556

Parasrampuria D, Matsushima N, Chen S et al (2013) Safety, tolerability, and pharmacokinetics of edoxaban in end-stage renal disease subjects undergoing hemodialysis. J Thromb Haemost 11(Suppl 2):225

Mendell J, Zahir H, Matsushima N et al (2013) Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13(5):331–342

Morishima Y, Kamisato C et al (2015) Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 143(2):241–247

Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association Practical Guide on the use of new oral anti-coagulants in patients with non-valvular atrial fibrillation. Europace 15:625–651